Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview

Prelude Therapeutics Incorporated

10/08/2026 14:27

Prelude Therapeutics Incorporated PRLD.OQ PRLD.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Prelude Therapeutics Incorporated is for a loss of 20 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Prelude Therapeutics Incorporated is $8.00, about 63.3% above its last closing price of $4.90
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.26
-0.25
-0.13
Beat
47.7
Dec. 31 2026
-0.12
-0.03
-0.20
Missed
-589.7
Sep. 30 2025
-0.36
-0.37
-0.26
Beat
28.8​
Jun. 30 2025
-0.44
-0.44
-0.41
Beat
6.7
​​Mar. 31 2025
-0.47
-0.47
-0.42
Beat
10.3
Dec. 31 2024
-0.46
-0.38
Beat
18​
Sep. 30 2024
-0.47
-0.47
-0.43
Beat
8.9
Jun. 30 2024
-0.43
-0.43
-0.46
Missed
-7
This summary was machine generated August 10 at 13:27 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)